These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 20473853)

  • 1. Association of diabetes mellitus with prostate cancer: nested case-control study (Prostate testing for cancer and treatment study).
    Turner EL; Lane JA; Donovan JL; Davis MJ; Metcalfe C; Neal DE; Hamdy FC; Martin RM
    Int J Cancer; 2011 Jan; 128(2):440-6. PubMed ID: 20473853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study.
    Dimitropoulou P; Martin RM; Turner EL; Lane JA; Gilbert R; Davis M; Donovan JL; Hamdy FC; Neal DE
    Br J Cancer; 2011 Mar; 104(5):875-81. PubMed ID: 21266978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study.
    Collin SM; Metcalfe C; Donovan JL; Athene Lane J; Davis M; Neal DE; Hamdy FC; Martin RM
    Eur J Cancer; 2009 Dec; 45(18):3254-61. PubMed ID: 19541477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A polymorphism in the glucokinase gene that raises plasma fasting glucose, rs1799884, is associated with diabetes mellitus and prostate cancer: findings from a population-based, case-control study (the ProtecT study).
    Murad AS; Smith GD; Lewis SJ; Cox A; Donovan JL; Neal DE; Hamdy FC; Martin RM
    Int J Mol Epidemiol Genet; 2010 Apr; 1(3):175-83. PubMed ID: 21537389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study).
    Murad AS; Down L; Davey Smith G; Donovan JL; Athene Lane J; Hamdy FC; Neal DE; Martin RM
    Int J Cancer; 2011 Mar; 128(6):1442-8. PubMed ID: 20506261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.
    Brindle LA; Oliver SE; Dedman D; Donovan JL; Neal DE; Hamdy FC; Lane JA; Peters TJ
    BJU Int; 2006 Oct; 98(4):777-82. PubMed ID: 16978272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results.
    Beckmann K; Crawley D; Nordström T; Aly M; Olsson H; Lantz A; Binti Abd Jalal N; Garmo H; Adolfsson J; Eklund M; Van Hemelrijck M
    JAMA Netw Open; 2019 Nov; 2(11):e1914689. PubMed ID: 31693126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alcohol consumption and PSA-detected prostate cancer risk--a case-control nested in the ProtecT study.
    Zuccolo L; Lewis SJ; Donovan JL; Hamdy FC; Neal DE; Smith GD
    Int J Cancer; 2013 May; 132(9):2176-85. PubMed ID: 23024014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer.
    Moore AL; Dimitropoulou P; Lane A; Powell PH; Greenberg DC; Brown CH; Donovan JL; Hamdy FC; Martin RM; Neal DE
    BJU Int; 2009 Dec; 104(11):1592-8. PubMed ID: 19549125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations between an obesity related genetic variant (FTO rs9939609) and prostate cancer risk.
    Lewis SJ; Murad A; Chen L; Davey Smith G; Donovan J; Palmer T; Hamdy F; Neal D; Lane JA; Davis M; Cox A; Martin RM
    PLoS One; 2010 Oct; 5(10):e13485. PubMed ID: 20976066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective study of plasma selenium levels and prostate cancer risk.
    Li H; Stampfer MJ; Giovannucci EL; Morris JS; Willett WC; Gaziano JM; Ma J
    J Natl Cancer Inst; 2004 May; 96(9):696-703. PubMed ID: 15126606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High rates of prostate-specific antigen testing in men with evidence of benign prostatic hyperplasia.
    Meigs JB; Barry MJ; Giovannucci E; Rimm EB; Stampfer MJ; Kawachi I
    Am J Med; 1998 Jun; 104(6):517-25. PubMed ID: 9674713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of diabetes and body mass index with levels of prostate-specific antigen: implications for correction of prostate-specific antigen cutoff values?
    Müller H; Raum E; Rothenbacher D; Stegmaier C; Brenner H
    Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1350-6. PubMed ID: 19383895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA.
    Severi G; Hayes VM; Neufing P; Padilla EJ; Tilley WD; Eggleton SA; Morris HA; English DR; Southey MC; Hopper JL; Sutherland RL; Boyle P; Giles GG
    Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1142-7. PubMed ID: 16775173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J; Högstedt B
    Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Height and prostate cancer risk: a large nested case-control study (ProtecT) and meta-analysis.
    Zuccolo L; Harris R; Gunnell D; Oliver S; Lane JA; Davis M; Donovan J; Neal D; Hamdy F; Beynon R; Savovic J; Martin RM
    Cancer Epidemiol Biomarkers Prev; 2008 Sep; 17(9):2325-36. PubMed ID: 18768501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. History of diabetes mellitus and risk of prostate cancer in physicians.
    Zhu K; Lee IM; Sesso HD; Buring JE; Levine RS; Gaziano JM
    Am J Epidemiol; 2004 May; 159(10):978-82. PubMed ID: 15128610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer association studies: pitfalls and solutions to cancer misclassification in the PSA era.
    Platz EA; De Marzo AM; Giovannucci E
    J Cell Biochem; 2004 Feb; 91(3):553-71. PubMed ID: 14755685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study.
    Kopec JA; Goel V; Bunting PS; Neuman J; Sayre EC; Warde P; Levers P; Fleshner N
    J Urol; 2005 Aug; 174(2):495-9; discussion 499. PubMed ID: 16006879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen screening and mortality from prostate cancer.
    Marcella SW; Rhoads GG; Carson JL; Merlino F; Wilcox H
    J Gen Intern Med; 2008 Mar; 23(3):248-53. PubMed ID: 18172740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.